November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
June 30th 2021
March 2nd 2021
Bepostastine solution provides comfort, safetyFebruary 15th 2010
Bepostastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) is safe and well-tolerated in healthy children as young as 3 years of age, according to results from a multicenter, prospective, double-masked, randomized, placebo-controlled trial.
Topical corticosteroid valuable option in allergic conjunctivitis careFebruary 15th 2010
For patients who are suffering with moderate to severe signs and symptoms of seasonal or perennial allergic conjunctivitis, loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb) is a safe and well-tolerated therapeutic option that can provide rapid clinical improvement, according to new research.
Efficacy of artificial tears tested under arid conditionsFebruary 15th 2010
An efficacy evaluation comparing two marketed artificial tears showed that a polyethylene-based product (Systane Ultra, Alcon Laboratories) resulted in statisically greater reductions in corneal and conjunctival staining than a glycerin/carboxymethylcellulose-based tear (Refresh Optive, Allergan).
A phase II study with a novel non-invasive iontopohoretic drug delivery system (EyeGate II Delivery System, EyeGate Pharma) shows that the device appears to optimize the delivery of a proprietary dexamethasone-derived corticosteroid solution (EGP-437) and improve significantly the signs and symptoms of dry eye, which may raise the bar in therapies for dry eye syndrome.
Cyclosporine cost-effective, improves life quality in analysisFebruary 15th 2010
Results of a utility analysis of cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) show that it is highly cost-effective and improves the quality of life in patients with moderate to severe dry eye disease that is unresponsive to conventional lubricant therapy.
Olopatadine provides adjuvant effectsFebruary 15th 2010
Analyses of data from two hybrid environmental studies evaluating olopatadine hydrochloride 0.2% once daily for the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis show that patients derive improvement in the frequency and/or severity of their nasal symptoms as a simultaneous benefit with relief of ocular allergy, according to Mark B. Abelson, MD.
Epinastine exhibits tolerability, efficacy in case study scenarioFebruary 15th 2010
The multimodal anti-allergy agent epinastine hydrochloride 0.05% (Elestat, Inspire Pharmaceuticals) is an ideal treatment option for the management of seasonal allergic conjunctivitis and is a particularly good choice in patients who have dry eye disease as a comorbidity, according to Laurie D. Barber, MD
1-year results show ongoing benefit of ranibizumab for diabetic macular edemaFebruary 1st 2010
An updated analysis of data from an ongoing phase II study of intravitreal ranibizumab treatment for diabetic macular edema shows that functional and anatomic benefits observed at 6-month primary efficacy endpoint are generally maintained at 1 year after switching to a "prn" dosing schedule.
Radiation, injections reduce treatment burden for age-related macular degenerationFebruary 1st 2010
A preliminary study of epimacular brachytherapy showed that radiation and antivascular endothelial growth factor injections reduced the treatment burden in patients with neovascular age-related macular degeneration.
Implant is new approach to uveitisFebruary 1st 2010
A single sustained-release dexamethasone intravitreal implant resulted in resolution of inflammation and improvement in visual acuity (VA) in patients with intermediate or posterior uveitis through 26 weeks in a multicenter, randomized, controlled clinical trial.
Fixed-combination therapies are compared in studiesJanuary 15th 2010
Pooled results from two randomized, investigator-masked parallel group clinical trials show that the fixed combination fo brimonidine tartrate 0.2%-timolol maleate 0.5% produced greater IOP lowering than the fixed combination of dorzolamidehydrochloride 2%-timolol maleate 0.5%, whether the fixed combination products were used alone or as an adjunct to treatment with a prostaglandin analogue.
Trends from Current Concepts in Ophthalmology are addressedNovember 15th 2009
As attendees gather for the Wilmer Eye Institute's 22nd annual Current Concepts in Ophthalmology meeting, they can expect the agenda to focus on clinical use and medical issues important to ophthalmology.
Interim results of pharmacokinetic study: Insert shows benefit as DME treatmentNovember 1st 2009
Interim results from the first human pharmacokinetic study of an investigational extended-release intravitreal device for the treatment of diabetic macular edema suggest that it has both significant efficacy and a favorable side effect profile.
Dexamethasone: Data show implant improves vision in patients with RVONovember 1st 2009
New data from phase III clinical trials of dexamethasone 0.7 mg intravitreal implant reaffirm that this novel pharmacotherapeutic intervention is well-tolerated and effectively improves vision in patients with macular edema secondary to a branch or central retinal vein occlusion.